Board of Directors

  • Philippe Peltier (Board Director, Auriga Partners representative)
  • Guy Paillaud (Board Director, Financière de l’Intendance representative)
  • Els Hubloux (Board member, Quest for Growth representative)
  • Hiroaki Tanaka (Board Observer, Debioinnovation representative)

Board of Directors biographies

Philippe Peltier
Board member, Auriga Partners

Philippe has been a Partner at Auriga Partners since 1999.
Philippe has been an early stage investor in numerous successful healthcare companies including Alantos Pharmaceuticals (acquired by Amgen), Innate Pharma (EuroNext Paris: IPH), Spine Next (acquired by Abbott), Targacept (Nasdaq: TRGT), Tigenix (EuroNext : TIG).
Philippe currently serves on the board of directors of several portfolio companies including, Cellnovo (United-Kingdom), Novagali Pharma (France) and Genocea Biosciences (United States).
Prior to joining Auriga Partners, Philippe was an equity analyst with HSBC-CCF Securities, covering biotech and biopharma public stocks. Philippe holds a MS in Molecular Biology from the University of Paris VII and a MS in finance from ESSEC (Paris).

Mr. Guy Paillaud
Board Director

Mr. Guy Paillaud is representing la Financière de l’Intendance at the Board of Directors of TcLand Expression SA. He is the Chairman of Beviguen and Neptis. He graduated from the University of Paris Dauphine, holds an Executive Master of Business Administration degree from HEC and is a Certified Public Accountant. He is a former Deputy Finance director of Promodes Group.

Els Hubloux
Board member,
Quest for Growth representative

Els Hubloux Senior Investment Manager Quest for Growth Els Hubloux has 8 years of venture capital experience, two year of equity research experience and four years of R&D experience in pharmaceutical companies. Previous directorships and observerships have included 4AZA, Algonomics, PharmaNeuroBoost and Pronota. She joined Quest Management as senior investment manager in July 2007, prior to which she was investment manager at KBC Private Equity from 2002 to 2007. From 2000 to 2002 she worked as a financial analyst for KBC Securities covering biotech stocks such as Actelion, Innogenetics and Tanox. Prior to joining the KBC group she worked for Abbott (1996-1998) and Merck (1998 – 2000). She holds a chemical engineering degree and MBA from the University of Brussels.

Dr Hiroaki Tanaka
Board Observer

Senior Diagnostics expert at Debiopharm (Switzerland). Dr Tanaka is a biotechnology/pharmaceutical R&D international executive with real business background and experience. Former Head of Stratified Medicine at Merck Serono, i.e. responsible for personalized medicine strategy through the definition of biomarker activities in all clinical trials. Former CIO and VP Bioinformatics at Genset, a leading biotech in genomics. He is a graduated PhD in Fundamental Pharmacology from Université Paris Sud (Paris XI), an Engineer from Ecole Polytechnique and has earned an Executive MBA from INSEAD.

Comments are closed.